Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
155.55
-2.51 (-1.59%)
At close: Mar 28, 2025, 4:00 PM
154.36
-1.19 (-0.77%)
Pre-market: Mar 31, 2025, 7:53 AM EDT

Company Description

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.

The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services.

The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.

This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies.

It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc.
Charles River Laboratories International logo
Country United States
Founded 1947
IPO Date Jun 23, 2000
Industry Diagnostics & Research
Sector Healthcare
Employees 20,100
CEO James Foster

Contact Details

Address:
251 Ballardvale Street
Wilmington, Massachusetts 01887
United States
Phone 781 222 6000
Website criver.com

Stock Details

Ticker Symbol CRL
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001100682
CUSIP Number 159864107
ISIN Number US1598641074
Employer ID 06-1397316
SIC Code 8731

Key Executives

Name Position
James C. Foster J.D. Chairman, President and Chief Executive Officer
Flavia H. Pease Corporate Executive Vice President and Chief Financial Officer
Birgit Girshick Corporate Executive Vice President and Chief Operating Officer
Joseph W. LaPlume J.D. Corporate Executive Vice President of Corporate Development and Strategy
Michael Gunnar Knell Corporate Senior Vice President and Chief Accounting Officer
Prof. Julie Frearson Ph.D. Corporate Senior Vice President and Chief Scientific Officer
Mark Mintz Corporate Senior Vice President and Chief Information Officer
Todd Spencer Corporate Vice President of Investor Relations
Matthew L. Daniel J.D. Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
Amy Cianciaruso Corporate Vice President and Chief Communications Officer

Latest SEC Filings

Date Type Title
Feb 21, 2025 8-K Current Report
Feb 20, 2025 144 Filing
Feb 19, 2025 10-K Annual Report
Feb 19, 2025 8-K Current Report
Jan 14, 2025 8-K Current Report
Dec 13, 2024 8-K Current Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 144 Filing
Nov 6, 2024 10-Q Quarterly Report